Home › Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection
 

Keywords :   


Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection

2015-07-28 12:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Company Granted FDA Priority Review with Target Action Date of January 28, 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Sarra Herzog, (201) 669-6570orInvestor:Joe Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: and food application treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Reddit shares jump after OpenAI ChatGPT deal
17.05Is China's bubble tea bubble about to burst?
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Business locked in expensive AI 'arms race'
17.05Is the move to electric cars running out of power?
More »